Prediction for HBsAg seroconversion in children with chronic hepatitis B
Open Access
- 4 December 2021
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-8
Abstract
Background: To establish a prediction of HBsAg seroconversion in children with chronic hepatitis B (CHB), so as to help clinicians to choose therapeutic strategy. Methods: A total of 63 children with HBeAg-positive CHB aged 1 to 17 years, who admitted to the fifth medical center of Chinese PLA general hospital and treated with interferon α (IFNα) 48 weeks were enrolled, the clinical data were measured. Based on the results of HBsAg seroconversion (HBsAg < 0.05 IU/mL and anti-HBsAg > 10 IU/L) at week 48, the patients were divided into HBsAg seroconversion (S) group and non-HBsAg seroconversion (NS) group. Multivariate COX regression was used to identify the impact factors associated with HBsAg seroconversion. A novel prediction index was established and the area under the receiver operating characteristic curve (AUROC) was used to assess the prediction for HBsAg seroconversion. Results: The 63 patients were divided into S group (20.6%, 13/63) and NS group (79.4%, 50/63). Univariate and multivariate analysis identified age, baseline intrahepatic cccDNA and serum HBsAg levels were independent impact factors for HBsAg seroconversion. Intrahepatic cccDNA was positively correlated with serum HBsAg (r = 0.464, p = 0.000). AUROC of HBV cccDNA was 0.83 (95% CI 0.71 to 0.95) and AUROC of baseline HBsAg was 0.77 (95% CI 0.61 to 0.92). Intrahepatic cccDNA ≤ 0.08 log10 copies/106 cell is regarded as cutoff value, the positive predictive value(PPV) and negative predictive value(NPV) for HBsAg seroconversion were 86.8% and 60.0%, respectively, with a sensitivity of 92.0% and specificity of 56.2%. HBsAg ≤ 3.68 log10 IU/mL is used as cut off value, the PPV and NPV for HBsAg seroconversion were 91.2% and 56.3%, respectively; the sensitivity and specificity was 86.0% of 69.2%, respectively. There was no statistical difference between them for predicting HBsAg seroconversion (p = 0.146). Conclusions: HBsAg seroconversion can be predicted by the baseline serum HBsAg or intrahepatic cccDNA in children with CHB. Using the index, clinicians can choose more reasonable therapeutic strategy and reduce the waste of medical resources.Keywords
Funding Information
- Beijing Science and Technology Planning Project (Z171100001017182)
- National Major Science and Technology Projects of China (2018zx10301-404)
This publication has 24 references indexed in Scilit:
- Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti-viral treatmentMolecular Medicine Reports, 2014
- HBsAg quantification: useful for monitoring natural history and treatment outcomeLiver International, 2013
- HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durabilityGut, 2013
- Baseline Hepatitis B Surface Antigen (Hbsag) as Predictor of Sustained Hbsag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2A and AdefovirAntiviral Therapy, 2013
- Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with real-time PCRClinica Chimica Acta, 2011
- Virologic and clinical characteristics of HBV genotypes/subgenotypes in 487 Chinese pediatric patients with CHBBMC Infectious Diseases, 2011
- Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha‐2a and adefovirJournal of Gastroenterology and Hepatology, 2011
- Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis BAntiviral Therapy, 2010
- Hepatitis B virus: molecular genotypes and HBeAg serological status among HBV-infected patients in the southeast of BrazilBMC Infectious Diseases, 2009
- Increased infiltration of intrahepatic DC subsets closely correlate with viral control and liver injury in immune active pediatric patients with chronic hepatitis BClinical Immunology, 2007